Clinical Trials for Gleevec/Sutent-resistant GIST

Main Trials Page | Search Trials | Clinical Trial Site List | Drug Watch List

First-line Trials | Gleevec/Sutent-resistant | All Trials | Recruiting Trials | Preventative (Adjuvant)Treatment Trials

The trials listed below are for Gleevec-resistant GIST (in most cases, Sutent-resistant as well). Click on the hyperlinks for more details about each trial. You will also have the opportunity to access trial site data later. Trials are sorted so that trials that are only for GIST appear first. Trials are also sorted so that trials in later phases sort higher on the list. Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.

 
Currently showing 20 of 44 trials
Page 1 of 3 | Next | Last

Nilotinib or Imatinib
Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (LANGIST)
Phase:  3
Category:  
KIT/PDGFRA inhibitor
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Site name unknown Monteria Monteria Colombia
Site name unknown Buenos Aires Buenos Aires Argentina
Site name unknown Belo Horizonte Belo Horizonte Brazil
Site name unknown Porto Alegre Porto Alegre Brazil
Site name unknown Barretos Barretos Brazil
Site name unknown Santo Andre Santo Andre Brazil
Site name unknown Jau Jau Brazil
Site name unknown Jatal Jatal Brazil
Site name unknown Rio de Janeiro Rio de Janeiro Brazil
Site name unknown Medellin Medellin Colombia
Site name unknown Hwasun-gun Hwasun-gun Republic of Korea
Site name unknown Seoul Seoul Republic of Korea
Site name unknown Daegu Daugu Republic of Korea
Site name unknown Panama Panama Panama
Site name unknown Bangkok Bankok Thailand
Khon Kaen University Khon Kaen Thailand
Prince of Songkla University Songkla Thailand
Site name unknown Caracas Caracas Venezuela


Nilotinib
Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor
Phase:  2
Category:  
KIT/PDGFRA inhibitor
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Site name unknown, Tel Aviv Tel Aviv Israel
Site name unknown, Tel Hashomer Tel Hashomer Israel
Site name unknown Jerusalem Jerusalem Israel


Nilotinib
Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Phase:  2
Category:  
KIT/PDGFRA inhibitor
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Site name unknown - Adana Adana Turkey
Site name unknown Izmir Turkey


Nilotinib and Imatinib
Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Phase:  2
Category:  
KIT inhibitor
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Fox Chase Cancer Center Philadelphia PA USA


Regorafenib (BAY 73-4506)
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Phase:  2
Category:  
KIT/PDGFRA inhibitor VEGFR inhibitor (TKI)
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Dana Farber Cancer Institute Boston MA USA
Fox Chase Cancer Center Philadelphia PA USA


Sorafenib (Nexavar, BAY 43-9006)
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
Phase:  2
Category:  
KIT/PDGFRA inhibitor+ VEGF inhibitor (TKI) + RAF inhibitor
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
University of Chicago Chicago IL USA
Memorial Sloan-Kettering Cancer Center New York NY USA
City of Hope Duarte CA USA
Illinois CancerCare Peoria IL USA
Cancer Care Specialists Decatur IL USA
USC-Norris Cancer Center Los Angeles CA USA
UC-Davis Sacramento CA USA
Central Illinois Hem/Onc Springfield IL USA
University of Michigan Ann Arbor MI USA
Medical College of Wisconsin Milwaukee WI USA


Sorafenib (Nexavar, BAY 43-9006)
Sorafenib for Imatinib/Sunitinib-failed GIST
Phase:  2
Category:  
KIT/PDGFRA inhibitor
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Samsung Medical Center Seoul Republic of Korea


STA-9090
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
Phase:  2
Category:  
HSP90 inhibitor
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Dana Farber Cancer Institute Boston MA USA
UCLA's Jonsson Comprehensive Cancer Center Los Angeles CA USA
Knight Cancer Institute at Oregon Health Sciences University (OHSU) Portland OR USA
Fox Chase Cancer Center Philadelphia PA USA


Sunitinib
Evaluation of Patients With Bulky GIST Using Sunitinib
Phase:  2
Category:  
KIT/PDGFRA inhibitor+ VEGF inhibitor (antibody)
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
UAB Comprehensive Cancer Center Birmingham AL USA


Imatinib + Panobinostat
LBH589 Plus Imatinib
Phase:  1
Category:  
HDAC inhibitor + KIT/PDGFRA inhibitor
NCT #:
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Universitatsklinikum Essen, West Germany Cancer Center Essen Germany
Helios Klinikum Bad Saarow Bad Saarow Germany


Nilotinib
Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST)
Phase:  
Category:  
KIT/PDGFRA inhibitor
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Asan Medical centre Seoul Republic of Korea


Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors
Phase:  4
Category:  
VEGFR inhibitor (TKI)
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
University Medical Center Nijmegen st Raboud Nijmegen Gelderland Netherlands


Everolimus
Treatment of Patients With RAD001 Who Have Progressive Sarcoma
Phase:  2
Category:  
mTOR inhibitor
Conditions:  
 Sarcoma
Site
City
State
Country
Site name unknown, Berlin Berlin Germany
Site name unknown, Munchen Munchen Germany
Site name unknown, Dusseldorf Dusseldorf Germany
Site name unknown, Mannheim 68135 Mannheim Germany
Site name unknown, Milan Milan Italy


Imatinib + IL-2
Imatinib + IL-2
Phase:  1
Category:  
KIT inhibitor + Immune stimulate
NCT #:
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Institut Gustave-Roussy Villejuif Cedex France


PLX3397
Safety Study of PLX108-01 in Patients With Solid Tumors
Phase:  1
Category:  
KIT inhibitor
Conditions:  
 Solid Tumors
Site
City
State
Country
TGen Clinical Research Services Scottsdale AZ USA
Evergreen Hematology and Oncology Spokane WA USA
Beth Israel Medical Center New York NY USA
Dana Farber Cancer Institute Boston MA USA
Massachusetts General Hospital Boston MA USA
Vanderbilt-Ingram Cancer Center Nashville TN USA


SF1126
A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K) Inhibitor, Given Twice Weekly by IV Infusion to Patients With Advanced or Metastatic Tumors
Phase:  1
Category:  
PI3K inhibitor
Conditions:  
 Solid Tumors
Site
City
State
Country
TGen Clinical Research Services Scottsdale AZ USA
Indiana University Simon Cancer Center Indianapolis IN USA
Arizona Cancer Center Tucson AZ USA
Emory Winship Cancer Institute Atlanta GA USA


Cixutumumab + Temsirolimus
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
Phase:  2
Category:  
IGF1R inhibitor + mTOR Inhibitor
Conditions:  
 Solid Tumors
Site
City
State
Country
Memorial Sloan-Kettering Cancer Center New York NY USA
University of Chicago Chicago IL USA


AUY922
Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients.
Phase:  1
Category:  
HSP90 inhibitor
Conditions:  
 Solid Tumors
Site
City
State
Country
Dana Farber Cancer Institute Boston MA USA
Washington University School of Medicine St. Louis MO USA
Nevada Cancer Institute Las Vegas NV USA
David Geffen School of Medicine at UCLA Los Angeles CA USA
Medical College of Georgia Augusta GA USA
Cancer Therapy and Research Center San Antonio TX USA
MD Anderson Cancer Center Houston TX USA
Site Name unknown, Bellinzona Bellinzona Switzerland
Site name unknown, London, UK London UK


BGT226
A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Phase:  1
Category:  
mTOR inhibitor PI3K inhibitor
Conditions:  
 Solid Tumors
Site
City
State
Country
Nevada Cancer Institute Las Vegas NV USA
Dana Farber Cancer Institute Boston MA USA
Massachusetts General Hospital Boston MA USA
Cancer Therapy and Research Center San Antonio TX USA
Hospital Vall d'Hebron Barcelona Spain
Princess Margaret Hospital Toronto ON Canada


GDC-0941 + GDC-0973
A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered Daily in Patients With Locally Advanced or Metastatic Solid Tumors
Phase:  1
Category:  
PI3K inhibitor + MEK inhibitor
Conditions:  
 Solid Tumors
Site
City
State
Country
Sarah Cannon Research Institute Nashville TN USA
Dana Farber Cancer Institute Boston MA USA
Karmanos Cancer Institute Detroit MI USA


 
20 of 
44 Trials Found Page 1 of 3 | Next | Last